Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 200

    1.

    DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis.

    van Riel PL, Fransen J.

    Arthritis Res Ther. 2005;7(5):189-90. Epub 2005 Aug 22.

    PMID:
    16207346
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.

    Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Veys EM, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F.

    Arthritis Res Ther. 2005;7(5):R1063-71. Epub 2005 Jul 8.

    PMID:
    16207323
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.

    van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH.

    Ann Rheum Dis. 2008 Dec;67(12):1697-701. Epub 2008 Jan 31.

    PMID:
    18245109
    [PubMed - indexed for MEDLINE]
    4.

    Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.

    Flendrie M, Creemers MC, van Riel PL.

    Rheumatology (Oxford). 2007 Jan;46(1):146-9. Epub 2006 Jun 16.

    PMID:
    16782732
    [PubMed - indexed for MEDLINE]
    Free Article
    5.

    A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.

    Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R.

    Rheumatology (Oxford). 2005 Apr;44(4):465-8. Epub 2005 Feb 3.

    PMID:
    15695306
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.

    Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, Vencovský J.

    Ann Rheum Dis. 2009 Aug;68(8):1285-9. Epub 2009 Apr 6.

    PMID:
    19351624
    [PubMed - indexed for MEDLINE]
    7.

    Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.

    Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L.

    Ann Rheum Dis. 2005 May;64(5):704-7. Epub 2004 Oct 14.

    PMID:
    15485995
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM).

    Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, Iikuni N, Nawata M, Amano K, Shinozaki M, Takeuchi T.

    Mod Rheumatol. 2007;17(1):28-32. Epub 2007 Feb 20. Erratum in: Mod Rheumatol. 2007;17(2):178.

    PMID:
    17278019
    [PubMed - indexed for MEDLINE]
    9.

    Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis.

    Kvalvik AG, Lefsaker L, Dyvik S, Brun JG.

    Joint Bone Spine. 2007 Dec;74(6):606-11. Epub 2007 Aug 9.

    PMID:
    17900958
    [PubMed - indexed for MEDLINE]
    10.

    Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.

    Bruns A, Nicaise-Roland P, Hayem G, Palazzo E, Dieudé P, Grootenboer-Mignot S, Chollet-Martin S, Meyer O.

    Joint Bone Spine. 2009 May;76(3):248-53. Epub 2009 Feb 8.

    PMID:
    19208451
    [PubMed - indexed for MEDLINE]
    11.

    Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab.

    Kameda H, Sekiguchi N, Nagasawa H, Amano K, Takei H, Suzuki K, Nishi E, Ogawa H, Takeuchi T.

    Mod Rheumatol. 2006;16(6):381-8. Epub 2006 Dec 20.

    PMID:
    17165001
    [PubMed - indexed for MEDLINE]
    12.

    Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2).

    Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, Nawata M, Kameda H, Iwata S, Amano K, Yamanaka H.

    Mod Rheumatol. 2008;18(2):146-52. Epub 2008 Feb 19.

    PMID:
    18283523
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    13.

    A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

    Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

    Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

    PMID:
    17049139
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab.

    Kuuliala A, Nissinen R, Kautiainen H, Repo H, Leirisalo-Repo M.

    Ann Rheum Dis. 2006 Jan;65(1):26-9. Epub 2005 Jun 7.

    PMID:
    15941839
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    16.

    Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.

    Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Reece R, Quinn M, Emery P.

    Arthritis Rheum. 2007 Apr 15;57(3):448-53. Erratum in: Arthritis Rheum. 2007 Jun 15;57(5):886.

    PMID:
    17394231
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis.

    Gardiner PV, Bell AL, Taggart AJ, Wright G, Kee F, Smyth A, McKane R, Lee J, Rooney ME, Whitehead E.

    Ann Rheum Dis. 2005 Mar;64(3):506-7. No abstract available.

    PMID:
    15708909
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    18.

    Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect.

    van Vollenhoven RF, Brannemark S, Klareskog L.

    Ann Rheum Dis. 2004 Apr;63(4):426-30.

    PMID:
    15020338
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    19.

    Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial.

    Fransen J, Moens HB, Speyer I, van Riel PL.

    Ann Rheum Dis. 2005 Sep;64(9):1294-8. Epub 2005 Apr 13.

    PMID:
    15829574
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

    Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

    Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

    PMID:
    16705046
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk